-
![Scientist, stress and headache for computer research, planning and data analysis, mistake or healthcare results-GettyImages-1713025725]( "5 QMS Blind Spots You Should Know About")
5 QMS Blind Spots You Should Know AboutCompanies often underestimate the complexity of standing up an eQMS. These are five of the most common issues that lead to regulatory and GMP exposure risk.
-
![Massachusetts Institute of Technology in Cambridge, MA-GettyImages-2143549630]( "New MIT Consortium Links Innovation With Real-World Biomanufacturing")
New MIT Consortium Links Innovation With Real-World BiomanufacturingIn one area, the Initiative for New Manufacturing is exploring whether microfactories, championed by the EV industry, can help biopharma iterate facility design faster.
-
![GettyImages-2167502114 bispecific antibodies]( "Comparing Process Development Approaches For Recombinant Proteins")
Comparing Process Development Approaches For Recombinant ProteinsExplore how adding a traceless tag enables streamlined affinity purification for recombinant proteins, and how this approach compares with a conventional process in development time, recovery, and purity.
-
![Multicolored antibodies immunoglobulin protein structures-GettyImages-1301300910]( "Host Cell Protein (HCP) Removal Post Virus Inactivation In mAb Processing")
Host Cell Protein (HCP) Removal Post Virus Inactivation In mAb ProcessingClarifying post–virus inactivation streams with a charged depth filter can remove precipitates while significantly reducing HCPs. See how a dual‑layer filtration approach supports stronger impurity control.
-
![GettyImages-1309780330-HPLC-lab-scientist-chromatography]( "Reducing Plastic Waste Using Syringeless Filters")
Reducing Plastic Waste Using Syringeless FiltersA streamlined approach to HPLC sample preparation can cut plastic waste by up to 79%. Find out how reducing consumables simplifies workflows and supports more sustainable, efficient lab operations.
-
![GettyImages-1153214501-filtration-funnel-lab]( "Microbial Recovery And Flow Performance With Membranes")
Microbial Recovery And Flow Performance With MembranesCompare membrane materials and pore sizes to assess their impact on flow rate and microbial recovery. See how fast filtration and ≥90% organism recovery offer guidance for selecting reliable membranes.
-
![Bioreactor, pharmaceutical manufacturing equipment-GettyImages-801080422]( "The Hidden Engineering Behind Successful Upstream Bioprocessing")
The Hidden Engineering Behind Successful Upstream BioprocessingIn upstream biopharmaceutical production, manufacturing is inseparable from biology, engineering, contamination control, and quality science.
-
![Pharmaceutical Manufacturing-GettyImages-2230291181]( "A Practical Look At Modern Downstream Processing For Biologics")
A Practical Look At Modern Downstream Processing For BiologicsPart 2 in a series about current bioprocessing practices explores the latest in separation, purification, sterile filtration and aseptic filling.
-
![GettyImages-1309776439-scientists-lab-analysis-manufacturing]( "Efficient Protein Purification Strategies")
Efficient Protein Purification StrategiesExamine two rapid, high‑throughput strategies for small‑scale protein separation, using either multimodal resins or ion exchange membranes to achieve efficient, low‑volume purification.
-
![GettyImages-2189138619 lab]( "Quick Detection Of Microorganisms With Membrane Filtration")
Quick Detection Of Microorganisms With Membrane FiltrationThe membrane filter technique offers a cost‑effective way to detect microbial contamination. See how it enables rapid detection and allows precise species identification using selective media.
-
![GettyImages-530437567-micro-tubes-for-centrifuge]( "Extraction, Isolation, And Purification Of DNA And RNA")
Extraction, Isolation, And Purification Of DNA And RNAEfficient DNA and RNA purification is essential as sequencing and expression studies scale. Discover a multi‑well format that enables reliable binding across plasmid, genomic, and total RNA workflows.
-
![GettyImages-1069264194-syringe-filter-vial-lab]( "Protect Your Columns And Your Peaks")
Protect Your Columns And Your PeaksLearn how thoughtful filter selection can protect LC systems, improve protein recovery, and support reliable chromatographic results with key performance data and solvent compatibility insights.
-
![GettyImages-1043640400-filtration-lab]( "Laboratory Cell Line Development")
Laboratory Cell Line DevelopmentEfficient cell line development demands reliable clone selection and early removal of candidates. Filtration and sample prep solutions can strengthen sterility, simplify workflows, and support decisions.
-
![GettyImages-1412800224-scientist-examining-filter-in-lab]( "How To Choose The Appropriate Filter Material For Every Sample")
How To Choose The Appropriate Filter Material For Every SampleMembrane compatibility plays a crucial role in reliable sample filtration. Knowing how different filter materials interact helps prevent common workflow issues and supports efficient filtration.
-
![GettyImages-2158013139-scientist-lab-working-on-machine]( "Solutions For Lab Scale Sterile Filtration And Clarification")
Solutions For Lab Scale Sterile Filtration And ClarificationFiltration strategies help maintain sample integrity by reducing particulates and controlling contaminants. Learn why choosing the right pore size supports consistent, reliable biological workflows.
ABOUT BIOSIMILAR MANUFACTURING
Biosimilars are considered to be low-cost substitutions for pricy, large-molecule biologics. However, biosimilars must meet the same quality, safety, and efficacy as their reference biologic. Manufacturing biosimilars requires a more complicated procedure than that of manufacturing small molecule generics. Companies manufacturing biosimilars are focused on creating a chemical structure that is as close as possible to that of the reference product. Failure rates and operational costs pose a challenge for those companies involved in manufacturing biosimilars compared to those manufacturing small molecule generics.
Small molecule generics are created using the same active pharmaceutical ingredient (API) and, therefore, are chemically identical to that of the originator medicine. The manufacturing process for small molecules comprises only one-fifth of the total in-process tests required to meet Good Manufacturing Practice compared to that of biologic medicines (50 vs. 250 in-process tests). In fact, the manufacturing process for a large molecule is so complex, it cannot be duplicated by two different manufacturers, as the cells used in biologic medicines are unique to the company manufacturing each biologic.
Manufacturing a biologic consists of genetically modifying a cell, which becomes the basis for a cell line used for the production of the necessary protein for the biologic medicine. The protein is then separated from the cells and purified. Biosimilars are created from small alterations to the manufacturing process which creates a molecule that is not identical but closely resembles the reference product. While the differences in the biosimilar molecule might be slight, these changes in the manufacturing process of a biosimilar can affect the efficacy and safety of a biosimilar compared to the reference biologic. Over the past decade, the manufacturing process for proteins has become more standardized and the required technology has become increasingly accessible, leading to reductions in biosimilars production costs. As a result, a greater number of companies have begun manufacturing biosimilars, while reference brand manufacturers are setting their sights on bolstering pipelines and manufacturing biobetters to maintain market share for their soon-to-be-off-patent reference products.
BIOSIMILAR DEVELOPMENT NEWS
- AEON Biopharma Abstract Accepted For Presentation At 2026 American Academy Of Neurology (AAN) Annual Meeting
- Provision Of Rs 13000 cr For BioPharma SHAKTI & 3 Dedicated Chemical Parks Is A Strategic Bet On India's Future
- Formycon Announces Positive Clinical Data For Keytruda Biosimilar Candidate FYB206 (pembrolizumab)
- SteinCares And Shilpa Biologicals Strike Into Licensing Agreement To Expand Access To Biosimilars Across Latin America
- Sandoz Confirms European Commission Approval For Ranluspec (ranibizumab), Further Strengthening Overall Biosimilars Leadership And Position In Ophthalmology